ATX-304
Phase 1- Indications
- Cardiometabolic diseases, Heart failure with preserved ejection fraction
Company intelligence / Profile preview
Betagenon
Umeå, Västerbottens län, Swedenbetagenon.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Phase 1
01
Overview
Betagenon develops small molecule compounds that activate AMP‑activated protein kinase (AMPK), targeting metabolic, cardiorenal, and inflammatory diseases. The company has received EU Horizon 2020 funding for its research and has demonstrated preclinical and early clinical progress with its AMPK activator programs. Detailed clinical results are not publicly available.
- Therapeutic areas
- Metabolic DisordersCardiovascularImmunology
- Modalities
- Small molecules (AMPK activators)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Received funding from EU’s Horizon 2020 research program; no major pharma partnerships disclosed.
Beyond the preview
Go deeper on Betagenon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Betagenon.